[
  {
    "ts": "2025-08-26T12:01:00+00:00",
    "headline": "PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology",
    "summary": "PAVmed Inc. (Nasdaq: PAVM) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has executed a non-binding letter of intent with Duke University to license, through a newly-formed subsidiary, Duke's technology to identify and facilitate treatment of advanced esophageal precancer (dysplasia) during upper endoscopy. This technology—a multi-modality probe combining an",
    "url": "https://finance.yahoo.com/news/pavmed-signs-letter-intent-license-120100704.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "7c54c1d3-a639-3e84-ac16-2a7255c063ad",
      "content": {
        "id": "7c54c1d3-a639-3e84-ac16-2a7255c063ad",
        "contentType": "STORY",
        "title": "PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology",
        "description": "",
        "summary": "PAVmed Inc. (Nasdaq: PAVM) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has executed a non-binding letter of intent with Duke University to license, through a newly-formed subsidiary, Duke's technology to identify and facilitate treatment of advanced esophageal precancer (dysplasia) during upper endoscopy. This technology—a multi-modality probe combining an",
        "pubDate": "2025-08-26T12:01:00Z",
        "displayTime": "2025-08-26T12:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/b33818e0ad32f6b512ca93166f23ff80",
          "originalWidth": 400,
          "originalHeight": 81,
          "caption": "PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. (PRNewsfoto/PAVmed Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TXqA2IOeOzkqLZ8AAl8Xtg--~B/aD04MTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b33818e0ad32f6b512ca93166f23ff80.cf.webp",
              "width": 400,
              "height": 81,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9IxL690t6qLa_7eHrHXrow--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b33818e0ad32f6b512ca93166f23ff80.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pavmed-signs-letter-intent-license-120100704.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pavmed-signs-letter-intent-license-120100704.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PAVMZ"
            },
            {
              "symbol": "PAVM"
            },
            {
              "symbol": "LUCD"
            },
            {
              "symbol": "DUK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]